RSS Content

Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings

MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, today announced preclinical data on the Company’s next-generation vectors are being presented today at the Association for Research in Vision and Ophthalmology (ARVO) and American Society of Gene & Cell Therapy (ASGCT) 2017 annual meetings.

“These presentations highlight the work underway to leverage our industry-leading capabilities in novel vector development,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies. “Discovered from our AAV-based directed evolution and rational design platform, these next-generation gene therapy vectors are designed to improve transduction in target tissues, ocular and systemic, and overcome the effects of neutralizing antibodies seen with conventional vectors. We are very excited about the preclinical data presented at ARVO on one of our novel variants, expanding our arsenal of vectors capable of transducing the retina via intravitreal injection.”

ARVO 2017 Poster Presentation
Title: Assessment of next-generation AAV variants in gerbil and non-human primate retina following intravitreal injection (Abstract #: 4097 - B0097)
Presenter: Annahita Keravala, Ph.D., Director Novel Vector Technology, Adverum Biotechnologies, Inc.
Date/Time: Wednesday, May 10, 2017, 8:30 - 10:15 a.m. ET
Session: Drug and Gene Therapy and Delivery
Location: Poster Board #B0097

ASGCT 2017 Poster Presentation
Title: Analysis of gene expression, tissue tropism, and safety of novel AAV variants in mice following intravenous administration
Presenter: Annahita Keravala, Ph.D., Director Novel Vector Technology, Adverum Biotechnologies, Inc.
Date/Time: Wednesday, May 10, 2017, 5:30 - 7:30 p.m. ET
Session: AAV Vectors I
Location: Exhibit Hall A & B South, #108

About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE).  Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Adverum’s plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies and product pipeline, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not consummate any plans or product or clinical development goals in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that Adverum’s resources will not be sufficient for Adverum to conduct or continue planned development programs and planned clinical trials, the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies, the risk that Adverum will not be able to successfully develop or commercialize any of its product candidates, and the risk that Adverum will fail to receive required regulatory approvals. Risks and uncertainties facing Adverum are described more fully in Adverum’s periodic reports filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts for Adverum:

Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
lpatterson@adverum.com

Tricia Truehart
Vice President
The Trout Group LLC
646-378-2953
ttruehart@troutgroup.com

Primary Logo

Adverum Biotechnologies, Inc.